Bellicum Pharmaceuticals, Inc. Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO Rimiducid-activated GoCAR-T® resulted in significant expansion and…
NexImmune Inc. NexImmune Granted Key US Patent for Core E+E Technology December 11, 2018
NuMat Technologies, Inc NuMat Technologies Partnership to Protect and Sustain Modern Warfighter with Dual-Use Technology December 7, 2018
Poseida Therapeutics Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting P-BCMA-101 showed a 100% ORR with…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel Results show high rates of…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018 Interim results suggest rivo-cel outcomes were comparable to a control study…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant Experience to date in clinical study shows high clinical…